Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Antiviral Therapeutics Market Research Report by Drug, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19

Published by 360iResearch LLP Product code 989540
Published Content info 197 Pages
Delivery time: 1-2 business days
Price
Back to Top
Antiviral Therapeutics Market Research Report by Drug, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19
Published: February 11, 2021 Content info: 197 Pages
Description

Title:
Antiviral Therapeutics Market Research Report by Drug (HIV Antiviral Drug, Hepatitis Antiviral Drug, Herpes Antiviral Drug, and Influenza Antiviral Drug), by Distribution (Hospital Pharmacy, Independent Pharmacy & Drug Store, and Online Pharmacy) - Global Forecast to 2025 - Cumulative Impact of COVID-19.

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

  • 1. The Global Antiviral Therapeutics Market is expected to grow from USD 56,891.37 Million in 2020 to USD 81,384.43 Million by the end of 2025.
  • 2. The Global Antiviral Therapeutics Market is expected to grow from EUR 49,883.43 Million in 2020 to EUR 71,359.41 Million by the end of 2025.
  • 3. The Global Antiviral Therapeutics Market is expected to grow from GBP 44,346.48 Million in 2020 to GBP 63,438.67 Million by the end of 2025.
  • 4. The Global Antiviral Therapeutics Market is expected to grow from JPY 6,071,750.80 Million in 2020 to JPY 8,685,780.96 Million by the end of 2025.
  • 5. The Global Antiviral Therapeutics Market is expected to grow from AUD 82,613.83 Million in 2020 to AUD 118,181.01 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Antiviral Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Drug, the Antiviral Therapeutics Market studied across HIV Antiviral Drug, Hepatitis Antiviral Drug, Herpes Antiviral Drug, and Influenza Antiviral Drug.
  • Based on Distribution, the Antiviral Therapeutics Market studied across Hospital Pharmacy, Independent Pharmacy & Drug Store, and Online Pharmacy.
  • Based on Geography, the Antiviral Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antiviral Therapeutics Market including Abbott Laboratories, AbbVie Inc., Atea Pharmaceuticals, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Inc., COCRYSTAL PHARMA, INC., Daiichi Sankyo Co. Ltd., Eli Lilly & Co., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Merck & Co., Pfizer Inc., Sanofi S.A., Schering-Plough Corporation, Venatorx Pharmaceuticals, Inc., and Vienna BioCenter.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™ FPNV Positioning Matrix:

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Antiviral Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™ Competitive Strategic Window:

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Antiviral Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antiviral Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antiviral Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Antiviral Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Antiviral Therapeutics Market?
  • 6. What are the modes and strategic moves considered suitable for entering the Global Antiviral Therapeutics Market?
Table of Contents
Product Code: MRR-DB2592C

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Drug Outlook
  • 3.4. Distribution Outlook
  • 3.5. Geography Outlook
  • 3.6. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of viral diseases like HIV and Hepatitis
      • 5.1.1.2. Application of antiviral therapeutics in pediatric care and respiratory diseases
      • 5.1.1.3. Increasing initiatives to curb viral diseases by public and private companies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with antiviral drug treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in molecular biology promoting drug development
      • 5.1.3.2. Improved testing and analysis of viral infections
    • 5.1.4. Challenges
      • 5.1.4.1. Moving towards the development of new drug development formula
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Antiviral Therapeutics Market, By Drug

  • 6.1. Introduction
  • 6.2. HIV Antiviral Drug
  • 6.3. Hepatitis Antiviral Drug
  • 6.4. Herpes Antiviral Drug
  • 6.5. Influenza Antiviral Drug

7. Global Antiviral Therapeutics Market, By Distribution

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Independent Pharmacy & Drug Store
  • 7.4. Online Pharmacy

8. Americas Antiviral Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Antiviral Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. South Korea
  • 9.10. Thailand

10. Europe, Middle East & Africa Antiviral Therapeutics Market

  • 10.1. Introduction
  • 10.2. France
  • 10.3. Germany
  • 10.4. Italy
  • 10.5. Netherlands
  • 10.6. Qatar
  • 10.7. Russia
  • 10.8. Saudi Arabia
  • 10.9. South Africa
  • 10.10. Spain
  • 10.11. United Arab Emirates
  • 10.12. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
    • 11.1.1. Quadrants
    • 11.1.2. Business Strategy
    • 11.1.3. Product Satisfaction
  • 11.2. Market Ranking Analysis
  • 11.3. Market Share Analysis
  • 11.4. Competitor SWOT Analysis
  • 11.5. Competitive Scenario
    • 11.5.1. Merger & Acquisition
    • 11.5.2. Agreement, Collaboration, & Partnership
    • 11.5.3. New Product Launch & Enhancement
    • 11.5.4. Investment & Funding
    • 11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles

  • 12.1. Abbott Laboratories
  • 12.2. AbbVie Inc.
  • 12.3. Atea Pharmaceuticals
  • 12.4. Aurobindo Pharma Limited
  • 12.5. Bristol-Myers Squibb Company
  • 12.6. Cipla Inc.
  • 12.7. COCRYSTAL PHARMA, INC.
  • 12.8. Daiichi Sankyo Co. Ltd.
  • 12.9. Eli Lilly & Co.
  • 12.10. F. Hoffmann-La Roche AG
  • 12.11. Gilead Sciences Inc.
  • 12.12. GlaxoSmithKline PLC
  • 12.13. Janssen Pharmaceuticals, Inc.
  • 12.14. Johnson & Johnson Services
  • 12.15. Merck & Co.
  • 12.16. Pfizer Inc.
  • 12.17. Sanofi S.A.
  • 12.18. Schering-Plough Corporation
  • 12.19. Venatorx Pharmaceuticals, Inc.
  • 12.20. Vienna BioCenter

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

List of Figures

  • FIGURE 1. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 13. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2025 (%)
  • FIGURE 14. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2025
  • FIGURE 16. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 17. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (%)
  • FIGURE 21. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2025
  • FIGURE 23. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, 2020 VS 2025 (USD MILLION)
  • FIGURE 25. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 27. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 28. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 29. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 30. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 31. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 32. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 33. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 34. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 35. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 36. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 37. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 38. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 39. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 40. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 41. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 42. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 43. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 47. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 48. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 49. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 50. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 51. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 52. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: 360IRESEARCH™ FPNV POSITIONING MATRIX
  • FIGURE 61. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: 360IRESEARCH™ MARKET SHARE ANALYSIS
  • FIGURE 62. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 63. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIVIRAL THERAPEUTICS MARKET, BY TYPE

List of Tables

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 51. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 52. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 53. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 54. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 55. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 56. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 57. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 58. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 59. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 60. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 61. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 62. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 63. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 64. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 65. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 66. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 67. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 68. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 69. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 70. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 71. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 72. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: SCORES
  • TABLE 73. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 74. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 75. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: RANKING
  • TABLE 76. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 77. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 78. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 79. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 80. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 81. GLOBAL ANTIVIRAL THERAPEUTICS MARKET: LICENSE & PRICING
Back to Top